Đánh giá độc tính của phác đồ Paclitaxel - Carboplatin trong điều trị ung thư phổi tế bào biểu mô tuyến giai đoạn IV chưa di căn não tại Bệnh viện Bạch Mai

Aim: To evaluate the toxicities of Paclitaxel Carboplatin regimen for treating stage IV adenocarcinoma lung cancer without brain metastases at Bach Mai Hospital. Patients and Methods: retrospective study in 51 stage IV adenocarcinoma lung cancer without brain metastases patients, treated. with PC regimen at Bach Mai Hospital from 1/2010 to 12/2012. Results: 92.2 percent of patients were over 40 years old, male/female ratio: 3.6/1. The functional symptoms were improved after treatment including cough, chest pain, osteo-pain. 35.3 percent of patient had responses, among these, one case had complete response (2 percent). Leukopenia grade 1,2: 35.3 percent; 2 percent of patients had leukopenia grade 3. hypohemoglobin grade 1,2: 35.3 percent. thrombopenia: 5.9 percent. No case of infection due to leukopenia. Elevated liver enzymes, kidney failure were rare and mild: 5.9 percent increased liver enzyme at grade 2; 3.9 percent renal failure at grade 1. Hair loss: 70.6 percent, peripheral nerve disease: 41.1 percent at grade 1, 2; arthralgia: 37.2 percent; nausea: 15.7 percent; vomiting: 3.9 percent; allergies: 5.9 percent. No interuption of treatment due to side effects. Conclusion: Paclitaxel-Carboplatin regimen for stage IV adenocarcinoma lung cancer was safe and well-tolerated.